What Antelope Dx does

Antelope Dx, operating commercially as Meep, is a Belgian deep-tech diagnostics company founded in 2018 and headquartered in Gent, Belgium. The company is developing the Meep Minilab, a palm-sized, clinical-grade home diagnostic device built on a proprietary silicon photonics platform that can quantify up to 20 biomarkers simultaneously at accuracy levels comparable to hospital lab analyzers, delivering results within minutes rather than requiring samples to be shipped to central laboratories.

The product strategy is a single-device, multi-cartridge platform with three current pipeline applications: a rapid test for Thrombotic Microangiopathies (Thrombotic Care) for acute triage and home follow-up, an anonymous self-test for sexually transmitted diseases (Intimate Health), and a therapy-branded monitoring device for chronic condition management (Therapy Monitoring). The underlying technology was developed through multiple competitive European grants and validated via clinical collaborations with hospitals, large pharma companies, and an academic partnership with Ghent University.

Revenue is intended to come from hardware sales of the Meep Minilab device and recurring single-use test cartridges, distributed direct-to-consumer with digital result transmission to clinics. The company is private, employs 11-50 people, and has raised approximately $21.7M across 2019-2020 from RMM, Saffelberg Investments, White Fund, and the Belgian innovation agency Agentschap Innoveren & Ondernemen. No current revenue figures, pricing, or post-2020 funding activity are disclosed.

Name

Antelope Dx

Legal name

Meep

Website

https://antelope-dx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Antelope Dx (operating as Meep) is a Belgian deep-tech company building a palm-sized, clinical-grade home diagnostic device on silicon photonics that quantifies up to 20 biomarkers in minutes, sold direct-to-consumer across thrombotic, STD, and chronic therapy monitoring applications.

Ownership category

akta.pro rank

Product category

Home Diagnostic Devices

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

At-Home Lab Testing & Diagnostics-Integrated Virtual Care (HLALAAAE)

akta.pro secondary industry

Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ)

Keywords

• Home diagnostic devices
• Point-of-care diagnostics
• Rapid biomarker testing
• Clinical grade testing
• Multi-biomarker analysis

Headquarters

HQ city

Zwijnaarde

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Home Diagnostic Device and Tests: Revenue generated from sale of the Meep minilab device and associated single-use test cartridges for various diagnostic applications including thrombotic care, sexual health, and therapy monitoring.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Antelope Dx (doing business as Meep) develops and sells the Meep Minilab, a palm-sized clinical-grade home diagnostic device built on silicon photonics technology that can quantify up to 20 biomarkers simultaneously within minutes. The company pairs the device with single-use test cartridges targeted at thrombotic care, sexual health (anonymous STD self-testing), and therapy-branded chronic condition monitoring, delivering instant digital results that can be transmitted to clinics.

Product overview

Meep is a unified platform built around a single core device — the Meep Minilab — a clinical-grade home laboratory that reads out various diagnostic tests using silicon photonics technology. The platform offers lab-quality biomarker quantification (up to 20 simultaneously) with instant results that can be digitally transmitted to clinics. The product portfolio consists of four distinct offerings: Thrombotic Care (rapid test for Thrombotic Microangiopathies for acute triage and home follow-up), Intimate Health Test (anonymous STD self-test), and Therapy Monitoring (a therapy-branded chronic condition monitoring device), all running on the Meep Minilab platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Meep Minilab Palm-sized clinical-grade home laboratory device that uses silicon photonics to quantify up to 20 biomarkers simultaneously with the accuracy and sensitivity of clinical lab analyzers, delivering results in minutes and enabling digital transmission to clinics.

Quantifiable outcome

• Quantify up to 20 biomarkers simultaneously
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Ghent UniversitycoreStrategic or Co-development PartnerAcademic partnership for technology development and validation. Ghent University logo appears alongside other European research collaborators indicating clinical collaboration on the silicon photonics-based diagnostic technology.
• European Research CollaboratorscoreStrategic or Co-development PartnerMultiple highly competitive European grants supporting the development of deep tech silicon photonics technology. Collaborations include clinical work with hospitals and large pharma companies for technology validation.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad is a global clinical diagnostics and life science research company with strong overlap in clinical chemistry and immunoassay instruments. Comparable as a broad incumbent whose instrument-plus-reagent model mirrors the economics Meep's reader-plus-cartridge approach needs to achieve.
• Roche Diagnostics: Roche Diagnostics is a global IVD leader with point-of-care platforms (e.g., cobas Liat) delivering clinical-grade molecular and immunoassay results in minutes. It is a broad incumbent in the space Meep targets; its installed base, regulatory assets, and reimbursement reach set the competitive bar for clinical adoption.
• Abbott Diagnostics: Abbott Diagnostics operates large-scale point-of-care and home testing franchises (e.g., Binax, i-Stat). It is a broad incumbent competing with Meep across clinical-grade point-of-care and decentralized testing, with established distribution and regulatory infrastructure.

Direct peers

• Tasso: Tasso develops at-home blood sample collection devices paired with laboratory analysis for clinical and consumer use. It competes with Meep in enabling clinical-grade diagnostics from home and shares the connected, decentralized-testing thesis, though its model centers on dried blood spot shipping rather than on-device multi-analyte readout.
• LetsGetChecked: LetsGetChecked provides at-home diagnostic test kits with online results and clinician follow-up across sexual health, hormonal, and chronic disease panels. Like Meep, it targets consumer demand for private, home-based diagnostic testing, though it relies on centralized lab processing rather than an in-home reader.
• Everlywell: Everlywell is a direct-to-consumer at-home diagnostics platform offering mail-in test kits across sexual health, chronic conditions, and wellness. It competes with Meep in the DTC home diagnostics channel, though Meep differentiates through an in-home reader with instant results rather than mail-in lab processing.
• myLAB Box: myLAB Box sells direct-to-consumer at-home STD and wellness test kits. It is a direct peer in Meep's Intimate Health / STD testing use case, sharing the same DTC stigma-removal value proposition, though without an in-home reader.
• Cue Health: Cue Health produces a connected, at-home molecular diagnostic reader and single-use test cartridges for consumer and clinical use, directly mirroring Meep's hardware-plus-cartridge DTC home diagnostic model. Both target clinical-grade accuracy from a small reader, though Cue has focused on respiratory pathogens while Meep expands across thrombotic, sexual health, and therapy monitoring.
• Healthy.io: Healthy.io turns smartphone cameras into clinical-grade home diagnostic devices (e.g., urinalysis, wound care). It is comparable to Meep as a smartphone-or-device-enabled home diagnostics platform targeting consumer-friendly, decentralized testing workflows.

Emerging players

• Babson Diagnostics: Babson Diagnostics is developing capillary-blood-based retail diagnostics with a small footprint reader. It overlaps with Meep in miniaturizing lab-grade diagnostics for non-traditional sites (retail, home) but remains a US-focused emerging player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antelope Dx